Class Action

Did Manufacturer of Low-T Drug Disclose Risks?

Posted in Class Action on May 16, 2014

Five individuals have filed a lawsuit against the manufacturer of Low-T testosterone therapy drug AndroGel.  The suit has alleged that AbbVie and Abbott Laboratories  concealed facts about AndroGel and serious side-effects associated with the drug. According to the suit, the manufacturer failed to adequately research the risks of stroke or heart attack from testosterone therapy,… read more…

Actos Litigation Continues

Posted in Class Action on May 12, 2014

Litigation involving the drug Actos (Pioglitazone) is continuing in the class actions posture following a verdict in a bellweather case in excess of $9 billion dollars. The manufacturer of Actos,Takeda Pharmaceutical Co., made more than $16 billion before Actos went generic in 2012.  While internal records show that Takeda knew about a link between Actos… read more…